ArticlePHAGE (New Rochelle, N.Y.)2024
Isolation and Characterization of Three Lytic Bacteriophages to Overcome Multidrug-, Extensive Drug-, and Pandrug-Resistant
Article in PHAGE (New Rochelle, N.Y.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The worrisome spread of multidrug-resistant (MDR) pathogens necessitates research on nonantibiotic therapeutics. Among these therapeutics, phage treatment uses bacteriophages (phages) as alternative antimicrobial agents. Objectives: This project evaluates the lytic efficiency of phage cocktails Methods: We utilized host range and genetic information to generate a three-phage cocktail capable of killing multiple clinical strains of Findings: The results showed that a cocktail of three phages (MMS1, MMS2, and MMS3) could lyse Conclusions: Notably, XDR and PDR isolates were sensitive to the phage cocktail, a prospective substitute for antibiotics that does not contribute to the growth of antibiotic resistance, suggesting that the phage cocktail might be useful for generating personalized phage therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.